Atryn Market Report 2026

Atryn Market Overview

• The Atryn market growth in the historic period has been driven by clinical need for antithrombin replacement, success in hereditary antithrombin deficiency management • Market expansion is supported by increasing diagnosis of inherited thrombophilia, rising surgical intervention rates • Growth Driver: Increase In Chronic Conditions Driving Growth Of The Atryn Market • Market Trend: Expansion Of CDMO Capabilities In Therapeutic Protein Production For Rare Diseases • North America was the largest region in 2025.

What Is Covered Under Atryn Market?

Atryn refers to a recombinant human antithrombin protein produced using genetically modified goats. It is used for the prevention of blood clots in patients with hereditary antithrombin deficiency, particularly in high-risk situations such as surgery or childbirth. The main route of administration of atryn market are intravenous (IV) administration, subcutaneous (SC) administration. IV administration involves delivering medication or treatments directly into a vein through an intravenous line. This method provides immediate drug absorption and precise dosage control, making it suitable for emergencies or situations requiring rapid therapeutic action. The multiple distribution channels involved are direct sales, retail pharmacie, and online pharmacies. The various applications include hereditary antithrombin deficiency, acquired antithrombin deficiency, and others used by several end-users such as hospitals, specialized clinics, and home care.

What Is The Atryn Market Growth Forecast?

The growth in the forecast period can be attributed to increasing diagnosis of inherited thrombophilia, rising surgical intervention rates, expansion of biologic anticoagulant use, improved clinician awareness, growth in personalized coagulation therapy. Major trends in the forecast period include growing use of recombinant antithrombin therapies, increased focus on rare coagulation disorders, expansion of preventive thrombosis management, improved surgical risk management in high risk patients, rising adoption of biologic anticoagulants.

Global Atryn Market Segmentation

1) By Route of Administration: Intravenous (IV) Administration, Subcutaneous (SC) Administration 2) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies 3) By Application: Hereditary Antithrombin Deficiency, Acquired Antithrombin Deficiency, Other Thrombosis-related Conditions 4) By End-User: Hospitals, Specialized Clinics, Home Care

What Are The Drivers Of The Atryn Market?

The rise in chronic conditions is expected to fuel the growth of the atryn market going forward. Chronic conditions are long-term health issues that persist and typically require continuous management or treatment. The rise in chronic conditions can be attributed to factors such as an aging population, unhealthy lifestyles, and improved healthcare access and management. Atryn, a recombinant antithrombin therapy, helps patients with chronic conditions by preventing harmful blood clots, thereby reducing the risk of severe complications and improving long-term health outcomes. For instance, in April 2022, according to a report published by the National Association of Chronic Disease Directors (NACDD), a US-based non-profit Public Health organization dedicated to chronic disease programs, almost 60 percent of adult Americans have at least one chronic disease, approximately 40% of American adults have multiple chronic conditions (MCC), and this is expected to cost the US economy $2 trillion dollars annually, or $8,600 per person by 2030. Therefore, the rise in chronic conditions is driving the growth of the atryn industry. The increasing focus on personalized medicine is expected to propel the growth of the atryn market going forward. Personalized medicine involves customizing medical treatments to fit an individual’s unique genetic makeup, environment, and lifestyle for optimal effectiveness. The increasing focus on personalized medicine stems from its potential to improve treatment efficacy, reduce adverse effects, optimize resource utilization, and address the growing demand. Personalized medicine benefits from atryn by enabling precise and targeted treatment for patients with specific antithrombin deficiencies, optimizing safety and effectiveness in preventing life-threatening clotting disorders during critical medical procedures. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based organization promoting the adoption of personalized medicine, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of the atryn industry.

Key Players In The Global Atryn Market

Major companies operating in the atryn market are rEVO Biologics Inc.

Global Atryn Market Trends and Insights

Major companies operating in the Atryn market are focusing on enhancing advanced biomanufacturing solutions, such as cell-culture-based recombinant protein production, to increase output efficiency, improve product quality, and meet the rising global demand for biologics. Cell-culture-based recombinant protein production refers to a biotechnological process in which genetically engineered cells, often mammalian, bacterial, or yeast cells. For instance, in October 2023, LFB Biomanufacturing, a France-based biotechnology company, launched a project to increase its bioproduction capacity at the Alès site with the support of the France 2030 plan. This expansion aims to boost the production of innovative therapies, particularly those derived from cell culture. It is a key strategic effort for LFB to significantly enhance its ability to manufacture therapeutic recombinant proteins and biological drugs in France, further advancing treatments for rare diseases and strengthening the nation’s biomanufacturing sector.

Regional Insights

North America was the largest region in the atryn market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Atryn Market?

The atryn market includes revenues earned by entities by recombinant human antithrombin, biologic drug formulations, and active pharmaceutical ingredients (APIs). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Atryn Market Report 2026?

The atryn market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the atryn industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.